MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors. The funds raised will primarily be used to finance the production and market launch of MerLion’s US FDA and Health Canada approved drug XtoroTM, an otic suspension containing finafloxacin for treatment of ear infections. In addition to existing investors such as HeidelbergCapital and Vl Partners, new strategic investors such as Denk Pharma GmbH & Co. KG have taken part in the round. Further details were not disclosed. “This is…